8 July 2025 - Norgine is pleased to announce that Swissmedic has approved the registration of Ifinwil (eflornithine) as monotherapy for the treatment of paediatric patients from one year with high-risk neuroblastoma.

“This milestone marks a further regulatory approval of Ifinwil for high-risk neuroblastoma, following approvals in the US, Israel and Australia,” said Jörg Plessl, VP and Head of Global Regulatory Affairs at Norgine. “We deeply appreciate Swissmedic and the other Project Orbis partners for their keen awareness of the distinct challenges associated with paediatric oncology. Their agility in utilizing adaptive regulatory pathways is crucial because the stakes are incredibly high when it comes to children’s lives. In these situations, speed and flexibility are not just advantageous, they can make all the difference.”

Read Norgine press release